SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2008 |
| Sector | Life Science |
| Revenue | 41M USD (2021) |
Albireo is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase III trial in ALGS, an ongoing Phase III study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The company has also completed a Phase I clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Merger) | 1 of 1 |
| State (Connecticut) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2016) | 1 of 1 |
